The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 08, 2016
Filed:
Oct. 12, 2012
Applicant:
Yale University, New Haven, CT (US);
Inventors:
William L. Jorgensen, Deep River, CT (US);
Karen S. Anderson, Guilford, CT (US);
Assignee:
YALE UNIVERSITY, New Haven, CT (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07C 255/54 (2006.01); A61K 31/4409 (2006.01); A61K 45/06 (2006.01); C07D 239/54 (2006.01); A61K 31/513 (2006.01); C07D 239/553 (2006.01); A61K 31/5377 (2006.01); A61K 31/277 (2006.01); A61K 31/536 (2006.01); A61K 31/505 (2006.01); C07D 251/42 (2006.01); A61K 31/53 (2006.01); C07D 239/10 (2006.01); C07D 405/12 (2006.01); C07D 471/04 (2006.01); A61K 31/4412 (2006.01); A61K 31/5025 (2006.01); C07D 213/57 (2006.01); C07D 213/69 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07C 255/54 (2013.01); A61K 31/277 (2013.01); A61K 31/4409 (2013.01); A61K 31/4412 (2013.01); A61K 31/505 (2013.01); A61K 31/5025 (2013.01); A61K 31/513 (2013.01); A61K 31/53 (2013.01); A61K 31/536 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 213/57 (2013.01); C07D 213/69 (2013.01); C07D 239/10 (2013.01); C07D 239/54 (2013.01); C07D 239/553 (2013.01); C07D 251/42 (2013.01); C07D 405/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract
The present invention is directed to novel catechol diether compounds, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV 1 and 2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.